TICKERNERD
Menu
OSTXOSTXHealthcare · Biotechnology

OSTX Stock Forecast: OS Therapies, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.59
+0.63% on the day

The 4 Wall Street analysts covering OS Therapies, Inc. hold a median 12-month price target of $8 — +403.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$73.3M
Ticker Nerd rank
29 / 100
Median analyst target
$8.00
Analysts covering
4
Total return, dividends reinvested
1W
−1.9%
1M
+1.9%
YTD
+13.6%
1Y
−33.7%
From 52W high
−36.4%
From 52W low
+37.1%
$1.16
$2.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OSTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OS Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Size
79
Volatility
60
Value
52
Momentum
38
Issuance
31
Revisions
30
Growth
23
Quality
11

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OSTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26OSTXHigh $13.00Median $8.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.00Median $8.00High $13.00

The green dot is the last close — the median target sits +403.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026Roth CapitalInitiatesBuy—
19 May 2026Lake StreetMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
5 Feb 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
9 Dec 2025D. Boral CapitalMaintainsBuy—
5 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025D. Boral CapitalMaintainsBuy—
18 Nov 2025Lake StreetMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
10 Oct 2025D. Boral CapitalMaintainsBuy—
30 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OSTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OSTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

OS Therapies, Inc. (OSTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
−5.7×

Cheaper than 97% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
471.7%

Higher than 99% of US stocks

Return on assets
−366.6%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OSTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OSTXOS Therapies, Inc.$73.3M
29
IBIOiBio, Inc.$71.0M
26
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
LONALeonaBio, Inc.$71.5M
44
PLRXPliant Therapeutics, Inc.$71.5M
66
RNTXRein Therapeutics, Inc.$70.0M
37
XBITXBiotech, Inc.$69.5M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OS Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OSTX news & analysis

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

Newsfile Corp · 17 Aug 2026neutral

OS Therapies reported its second quarter 2026 financial results and provided regulatory updates. The company announced up to $10 million in debt financing (with $5 million funded at the first closing), outlined upcoming FDA Type C and MHRA statistical methods meetings, and noted interim and final 3-year Overall Survival data timelines supporting planned BLA and Conditional MAA submissions for OST-HER2 in metastatic osteosarcoma. The U.K. also waived the Pediatric Investigation Plan (PIP) requirement for the program.

Why it matters — OSTX watchers would care because these updates clarify the company's financing, pending FDA/MHRA regulatory meetings, and data-readout timelines that underpin progress toward BLA and Conditional MAA submissions for OST-HER2.

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Newsfile Corp · 13 Aug 2026positive

OS Therapies announced that the U.S. FDA granted its requested Type C Statistical Methods meeting to review 2.5-year overall survival data from the Phase 2b trial of OST-HER2 in fully resected, pulmonary metastatic osteosarcoma, with the meeting expected in mid-September 2026. The company also reported a sustained overall survival benefit between the 2-year and 2.5-year timepoints, and noted that a parallel U.K. MHRA Statistical Methods meeting was granted, with interim 3-year OS data expected in early September 2026.

Why it matters — This FDA meeting could lead to further regulatory decisions on OST-HER2 regarding the appropriate comparator arm, RMAT designation, and Rolling Review, signaling meaningful progress for OSTX's lead candidate.

FAQ

Frequently asked questions about OSTX stock

What is the OSTX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering OS Therapies, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSTX stock a buy right now?

Of the 4 analysts covering OS Therapies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OS Therapies, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSTX?

As at 22 Aug 2026, OS Therapies, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will OSTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +403.1% from the last close, and Ticker Nerd's factor model ranks OS Therapies, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSTX stock forecast for 2030?

No analyst covering OS Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $13 over the next 12 months.

How has OSTX stock performed over the past year?

OS Therapies, Inc. returned -33.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OS Therapies, Inc. do?

Os Therapies Inc. is a biotechnology company focused on the development and commercialization of innovative cancer treatments.

What is the latest news on OSTX?

The most recent item we track (Newsfile Corp, 17 Aug 2026): "OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates". OS Therapies reported its second quarter 2026 financial results and provided regulatory updates. The company announced up to $10 million in debt financing (with $5 million funded at the first closing), outlined upcoming FDA Type C and MHRA statistical methods meetings, and noted interim and final 3-year Overall Survival data timelines supporting planned BLA and Conditional MAA submissions for OST-HER2 in metastatic osteosarcoma. The U.K. also waived the Pediatric Investigation Plan (PIP) requirement for the program.

Company

About OS Therapies, Inc.

Os Therapies Inc. is a biotechnology company focused on the development and commercialization of innovative cancer treatments. Their primary function is to research and produce therapies aimed at improving the prognosis and quality of life for cancer patients. The company is particularly engaged in the immunotherapy sector, conducting trials and developing products that help harness the body’s immune system to fight cancer. Os Therapies Inc. plays a significant role in the biotechnology and pharmaceutical industries by striving to bring transformative solutions to oncological challenges. As part of the broader healthcare sector, their work contributes to advancements in personalized medicine and addresses pressing needs in cancer treatment methodologies. Through its cutting-edge research and dedicated approach, Os Therapies Inc. seeks to make impactful contributions to both patients' lives and the scientific community's understanding of cancer treatment.

CEO Mr. Paul A. Romness M.P.H. · 4 employees · United States · https://ostherapies.com